All data are based on the daily closing price as of April 4, 2025
c

Chugai Pharmaceutical

4519.TSE
45.45 USD
0.24
+0.53%
Created with Highcharts 11.1.0Chart context menu6 Jan13 Jan20 Jan27 Jan3 Feb10 Feb17 Feb24 Feb3 Mar10 Mar17 Mar24 Mar31 MarJan '23Jan '23Apr '23Apr '23Jul '23Jul '23Oct '23Oct '23Jan '24Jan '24Apr '24Apr '24Jul '24Jul '24Oct '24Oct '24Jan '25Jan '25ZoomView 1 month1mView 3 months3mView 6 months6mView year to dateYTDView 1 year1yView allAll4 Jan 20254 Apr 2025

Overview

Last close
45.45 usd
Market cap
74.79B usd
52 week high
52.91 usd
52 week low
28.98 usd
Target price
53.53 usd

Valuation

P/E
29.266
Forward P/E
26.0417
Price/Sales
9.6797
Price/Book Value
5.7358
Enterprise Value
67.21B usd
EV/Revenue
8.4658
EV/EBITDA
18.2844

Key financials

Revenue TTM
8.00B usd
Gross Profit TTM
5.68B usd
EBITDA TTM
3.92B usd
Earnings per Share
1.61 usd
Dividend
0.67 usd
Total assets
14.13B usd
Net debt
-3.46B usd

About

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology. The company was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
  • Symbol
    4519.TSE
  • Exchange
    TSE
  • Isin
    JP3519400000
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • CEO
    Dr. Osamu Okuda
  • Headquarter
    Chuo
  • Web site
    https://www.chugai-pharm.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top